Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
BioVie Inc. is a clinical-stage biopharmaceutical company focused on the development of novel drug therapies for neurodegenerative diseases and advanced liver disease. The company operates within the biotechnology and life sciences industries, with an emphasis on central nervous system (CNS) disorders and hepatic conditions that have significant unmet medical needs. BioVie does not currently generate commercial revenue, as its activities are centered on research and development rather than product commercialization.
The company’s primary value drivers are its proprietary drug candidates, most notably NE3107, an orally administered small molecule being evaluated for neurodegenerative and neuroinflammatory conditions, and BIV201, a continuous infusion therapy designed to treat complications of advanced liver cirrhosis. BioVie’s strategic positioning is based on targeting disease pathways involving inflammation, insulin signaling, and metabolic dysfunction. BioVie was originally founded in 2000 and has evolved through restructurings and asset acquisitions to focus on its current CNS and liver disease pipeline, becoming publicly traded through its listing on Nasdaq.
Business Operations
BioVie’s operations are organized around two primary clinical development programs: NE3107 Program and BIV201 Program. The NE3107 Program focuses on neurological and neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease, leveraging the compound’s proposed anti-inflammatory and insulin-sensitizing mechanisms. The BIV201 Program targets patients with decompensated cirrhosis, aiming to improve hemodynamics and renal function through continuous infusion therapy in acute care settings.
The company conducts its activities primarily through outsourced clinical research organizations, manufacturing partners, and academic or clinical trial sites rather than maintaining large internal laboratory infrastructure. BioVie operates as a single reporting segment and does not maintain revenue-generating subsidiaries. Its intellectual property portfolio consists of licensed and internally developed patents related to its drug candidates and delivery methods. Operations are primarily domestic, with international clinical trial activity depending on study design and regulatory requirements.
Strategic Position & Investments
BioVie’s strategic direction is centered on advancing its lead clinical assets through late-stage clinical trials and regulatory pathways, with the objective of eventual commercialization or strategic partnering. Growth initiatives are focused on clinical trial execution, regulatory engagement with the U.S. Food and Drug Administration, and potential expansion of indications for NE3107 beyond its initial target populations.
The company has historically pursued growth through targeted acquisitions of drug assets rather than broad-based mergers. Notable investments include the acquisition of rights to NE3107, which became the cornerstone of BioVie’s CNS strategy. BioVie does not report ownership of multiple operating subsidiaries or a diversified investment portfolio, and available public disclosures indicate that resources are concentrated on advancing its existing pipeline rather than on venture investments or unrelated technologies.
Geographic Footprint
BioVie is headquartered in the United States, with its principal executive offices located in Santa Monica, California. The company’s operational footprint is primarily U.S.-based, reflecting its focus on domestic clinical trials, regulatory oversight, and corporate management.
Internationally, BioVie’s presence is limited and largely indirect, consisting mainly of clinical trial sites and service providers engaged on a project basis. While its drug candidates are intended for global markets, the company does not maintain permanent offices or manufacturing facilities outside the United States. Its international influence is therefore developmental rather than commercial at this stage.
Leadership & Governance
BioVie is led by an executive team with experience in biotechnology, pharmaceuticals, and corporate finance. The leadership emphasizes capital discipline, clinical execution, and regulatory strategy, with a stated focus on advancing therapies for serious diseases lacking effective treatment options.
Key executives include:
- Cuong Do – President and Chief Executive Officer
- Joseph E. Thomas – Chief Financial Officer
- Joseph A. Christie – Chief Operating Officer
- Jonathan Adams – Chief Accounting Officer
The company is governed by a board of directors that provides oversight on strategy, risk management, and corporate governance, consistent with requirements for publicly traded U.S. biotechnology companies.